Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 3,25 M
EBIT 2016 -23,8 M
Net income 2016 -23,5 M
Debt 2016 1,50 M
Yield 2016 -
Sales 2017 10,9 M
EBIT 2017 -16,8 M
Net income 2017 -16,7 M
Debt 2017 3,93 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 34,9x
EV / Sales2017 10,7x
Capitalization 112 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
04/18Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : - Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
11/29 ONXEO : Strengthens AsiDNA Patent Protection in Europe
11/29 ONXEO : to Participate in the Guggenheim Securities 4th Annual Boston Healthcare..
07/07 ONXEO COLLABORATES WITH THE ROYAL CO : Onxeo samarbejder med Royal College of Su..
07/05 ONXEO : Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP..
07/04 ONXEO RECEIVES USPTO NOTICE OF ALLOW : Onxeo modtager “Notice of Allowance..
06/27 ONXEO ADVANCES DEVELOPMENT PLAN FOR : Onxeo offentliggør udviklingsplan for det..
06/27 ONXEO : advances development plan for first-in-class signal interfering DNA comp..
06/03 ONXEO : Announces Development of Beleodaq Oral Formulation Opening New Opportuni..
06/02 ONXEO ANNOUNCES DEVELOPMENT OF BELEO : Onxeo offentliggør udviklingen af en oral..
05/02 PUBLICATION OF 2015 REFERENCE DOCUME : Offentliggørelse af Reference Document fo..
More news
Sector news : Pharmaceuticals - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 8,10 €
Spread / Average Target 240%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Graham K. Dixon Chief Scientific Officer
David Horn Solomon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA119
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results